We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
febit Receives European Union Patent for Synthesis of Minimal Genomes
News

febit Receives European Union Patent for Synthesis of Minimal Genomes

febit Receives European Union Patent for Synthesis of Minimal Genomes
News

febit Receives European Union Patent for Synthesis of Minimal Genomes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "febit Receives European Union Patent for Synthesis of Minimal Genomes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

febit announced the receipt of an EU patent, #EP 1 728 860B1, for its technology to synthesize minimal genomes.

The new patent protects febit’s technology for combining genes to construct a minimal functional genome or parts of it. The EU patent complements earlier patents on the synthesis of oligonucleotides for gene-assembling.

A minimal genome contains only the genetic information which is required to sustain life of a certain organism under predefined conditions. Minimal genomes help to identify essential genes and investigate the isolated activity of interesting genes in minimal cells. The synthesis of minimal genomes complements febit’s portfolio which contains groundbreaking technologies for the exploration of the genome. HybSelect, for example, is a technology for the enrichment of interesting genes for targeted resequencing. febit’s miRNA profiling enables the discovery and evaluation of new biomarker signatures for various diseases.
Advertisement